Mosaique Diagnostic

Executive Summary

Mosaique Diagnostic is a German clinical proteomics company specializing in capillary electrophoresis coupled to mass spectrometry (CE-MS) for early-stage disease diagnosis. Founded in 2000 and based in Hannover, the company offers highly innovative diagnostic services to patients, doctors, academic institutions, and pharmaceutical companies. Its proprietary CE-MS platform enables the detection of severe diseases—such as chronic kidney disease, bladder cancer, and coronary artery disease—at early, more treatable stages by analyzing peptide patterns in urine. Despite being a private company with limited public financial disclosures, Mosaique has established a strong scientific foundation with numerous publications supporting its technology. The company's core value proposition lies in shifting from reactive to preventive medicine, potentially reducing healthcare costs and improving patient outcomes. However, as a smaller player in the competitive diagnostics landscape, Mosaique faces challenges in scaling adoption and securing commercial traction. The company's ability to demonstrate clinical utility in large-scale studies and form strategic partnerships will be critical for future growth.

Upcoming Catalysts (preview)

• TBDPublication of key clinical validation study for bladder cancer or CKD detection60% success
• TBDStrategic partnership with major pharma or diagnostic distributor40% success
• TBDCE marking or FDA clearance for a new diagnostic panel30% success